CRISPR

CRISPR1-pgrmc2

ID

ZDB-CRISPR-200225-41

Name

CRISPR1-pgrmc2

Previous Names

None

Target

pgrmc2 (1)

Sequence

5' - GGGGCCGGTCTCGGTTTAGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
ecu10	pgrmc2

Expression

Gene expression in Wild Types + CRISPR1-pgrmc2

No data available

Phenotype

Phenotype resulting from CRISPR1-pgrmc2

No data available

Phenotype of all Fish created by or utilizing CRISPR1-pgrmc2

Phenotype	Fish	Conditions	Figures
ovarian follicle stage IV decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 3 from Wu et al., 2019
oocyte stage III pgr expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 3 from Wu et al., 2019
ovary lhcgr expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
oocyte stage IV mmp9 expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
liver igf1 expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
ovary cyp11a1.1 expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
ovary cyp17a1 expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
ovarian follicle stage III decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 3 from Wu et al., 2019
brain hsd3b1 expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
ovary cyp19a1a expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
ovary decreased size, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 3 from Wu et al., 2019
oocyte stage III adamts1 expression increased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
oocyte maturation decreased process quality, ameliorated	pgrmc2^ecu10/ecu10	chemical treatment: progestin	Fig. 4 from Wu et al., 2019
ovary esr2b expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
oocyte stage IV adamts9 expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
oocyte stage IV adam8b expression increased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
ovary egfra expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
ovary fshr expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
ovary star expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
oocyte stage IV pgr expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 3 from Wu et al., 2019
oocyte maturation decreased process quality, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
egg-laying behavior decreased frequency, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 3 from Wu et al., 2019
ovarian follicle stage II decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 3 from Wu et al., 2019
ovary hsd17b1 expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
ovary esr1 expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
ovary esr2a expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
ovarian follicle stage I increased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 3 from Wu et al., 2019
ovary ar expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
reproductive process decreased efficacy, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 3 from Wu et al., 2019
ovary hsd3b1 expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
brain fshb expression decreased amount, abnormal	pgrmc2^ecu10/ecu10	standard conditions	Fig. 5 from Wu et al., 2019
oocyte stage III pgr expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 3 from Wu et al., 2019
female organism decreased fecundity, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 1 from Wu et al., 2019
oocyte stage IV adamts8a expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
ovary oocyte stage IV increased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 2 from Wu et al., 2019
oocyte stage IV mmp9 expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
female organism decreased fertility, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 1 from Wu et al., 2019
ovulation decreased occurrence, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 2 from Wu et al., 2019
oocyte stage IV adamts9 expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
oocyte maturation process quality, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 2 from Wu et al., 2019
oocyte stage IV adamts1 expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
oocyte stage IV pgr expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 3 from Wu et al., 2019
oocyte stage IV mmp2 expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
ovary oocyte stage V decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 2 from Wu et al., 2019

Citations